Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
A Panobinostat Presurgery
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Duke University
- Registration Number
- NCT01115036
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 28
- Registration Number
- NCT01105312
- Locations
- 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT01083602
- Locations
- 🇺🇸
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta, Georgia, United States
🇺🇸Duke University Medical Center Dept. of DUMC (4), Durham, North Carolina, United States
🇺🇸MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT01056601
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT01034163
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
🇺🇸Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
🇺🇸Northwestern University Oncology, Chicago, Illinois, United States
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 767
- Registration Number
- NCT01023308
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00967044
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
- Conditions
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00962507
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Medical Group, Pasadena, California, United States
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00931762
- Locations
- 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
- Conditions
- Recurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaNodal Marginal Zone B-cell LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Grade 3 Follicular Lymphoma
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 124
- Registration Number
- NCT00918333
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.